Fathi, A. T., Blonquist, T. M., Hernandez, D., Amrein, P. C., Ballen, K. K., McMasters, M., Avigan, D. E., Joyce, R., Logan, E. K., Hobbs, G., Brunner, A. M., Joseph, C., Perry, A. M., Burke, M., Behnan, T., Foster, J., Bergeron, M. K., Moran, J. A., Ramos, A. Y., Som, T. T., Rae, J., Fishman, K. M., McGregor, K. L., Connolly, C., Neuberg, D. S., & Levis, M. J. (2018). cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer, 124(2), 306–314. http://access.bl.uk/ark:/81055/vdc_100055537249.0x00005f